SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
Key Highlights
- ➤Vivos acquires 11% of SOD Sciences and 50% stakes in its pseudohypoxia patent and test.
- ➤Vivos exchanges $12 million of Series D preferred stock, convertible into 80 million common shares.
- ➤Partners split 50/50 contribution margin on every ReBalU Primed Cell Test sold.
- ➤ReBalU Primed Cell Test targets more than 2,600 U.S. sleep centers and chronic-disease practices.
- ➤SOD begins an Institutional Review Board study at Cleveland Clinic Weston for its Test/Treat/Retest Protocol.
Expert Statements
Joseph M. Salvani, Chief Executive Officer of SOD Sciences
“We are thrilled to partner with Vivos and to welcome Vivos as a strategic investor in SOD Sciences. Pseudohypoxia is a state in which a cell behaves as if it is starved of oxygen even when oxygen is present”
Joseph M. Salvani, Chief Executive Officer of SOD Sciences
“The cell switches on its hypoxia survival program, led by HIF‑1α, and shifts its metabolism toward the pattern of chronic disease and cancer. Of all the ways hypoxia harms the body, the repeated cycle of desaturation and reoxygenation is the most important. It hits tens of millions of Americans every night, and most of them have no idea. Our test finds them early, and Vivos's appliances and the ReBalU Protocol are ideally suited to treat exactly what the test finds. Vivos stops the cycles, and ReBalU rebuilds the reserve.”
Daniel J. Walsh, Chief Operating Officer of SOD Sciences, Inc.
“The most valuable patients in the U.S. medical system are the ones already diagnosed, already in a clinician's care, and already carrying the chronic conditions that drive cost, and today they are scattered across thousands of practices.”
Daniel J. Walsh, Chief Operating Officer of SOD Sciences, Inc.
“This transaction aggregates them. Through American Health Associates, the Sleep Center of Nevada, Cleveland Clinic Weston, and more than 2,600 sleep centers, Vivos and SOD now reach 500,000 identified patients who need exactly what we sell. Vivos treats the airway, ReBalU restores the cell's antioxidant reserve, and the pseudohypoxia test shows whether it is working and brings the patient back every ninety days. No other company owns all three, and every new clinic we add increases the value of the whole. Between Vivos's products, ReBalU, and this test, we are positioned to lead a revaluation of Vivos.”
VERO BEACH, FL / ACCESS Newswire / October 20, 2026 / SOD Sciences, Inc. ("SOD Sciences" or "SOD") today announced the closing of its strategic partnership with Vivos Therapeutics, Inc. (Nasdaq:VVOS) ("Vivos"). Vivos has acquired an 11% equity interest in SOD Sciences, a 50% ownership interest in SOD's pseudohypoxia patent, and a 50% ownership interest in SOD's pseudohypoxia early‑warning test, the ReBalU Primed Cell Test, in exchange for $12,000,000 of Vivos Series D Convertible Preferred Stock, convertible at $0.15 per share into 80,000,000 shares of Vivos common stock and subject to a 4.99% beneficial ownership blocker. SOD retains ownership of its other patents and its ReBalU Protocol.
The partnership at a glance * A strategic investor. Vivos, a Nasdaq‑listed leader in the treatment of obstructive sleep apnea, becomes an 11% shareholder in SOD Sciences, and SOD becomes a holder of Vivos convertible preferred stock. * A shared patent. SOD and Vivos each own 50% of SOD's pseudohypoxia patent. * A shared test. SOD and Vivos share 50/50 in the contribution margin on every ReBalU Primed Cell Test sold, through every channel, by either company. * ReBalU for Vivos customers. SOD and Vivos market the ReBalU Protocol to Vivos's customers on a 50/50 basis. * A national market. The ReBalU Primed Cell Test is marketed nationwide, to the more than 2,600 sleep centers in the United States and to chronic‑disease practices. * Nearly 500,000 patients. SOD's channels with Cleveland Clinic Weston, American Health Associates (AHA), and Vivos target nearly 500,000 patients with chronic disease. The ReBalU Protocol
Get started
Create a free account to read the full story.